These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Asakura M, Matsumura R, Itoh M. Methods Find Exp Clin Pharmacol; 1995 Nov; 17 Suppl C():64-9. PubMed ID: 8750798 [Abstract] [Full Text] [Related]
3. The roles of CYP2D6 and stereoselectivity in the clinical pharmacokinetics of chlorpheniramine. Yasuda SU, Zannikos P, Young AE, Fried KM, Wainer IW, Woosley RL. Br J Clin Pharmacol; 2002 May; 53(5):519-25. PubMed ID: 11994058 [Abstract] [Full Text] [Related]
8. Assessment of individual CYP2D6 activity in extensive metabolizers with renal failure: comparison of sparteine and dextromethorphan. Kévorkian JP, Michel C, Hofmann U, Jacqz-Aigrain E, Kroemer HK, Peraldi MN, Eichelbaum M, Jaillon P, Funck-Brentano C. Clin Pharmacol Ther; 1996 May; 59(5):583-92. PubMed ID: 8646830 [Abstract] [Full Text] [Related]
10. Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test. Laine K, Tybring G, Härtter S, Andersson K, Svensson JO, Widén J, Bertilsson L. Clin Pharmacol Ther; 2001 Oct; 70(4):327-35. PubMed ID: 11673748 [Abstract] [Full Text] [Related]
18. Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. LLerena A, de la Rubia A, Berecz R, Dorado P. Pharmacopsychiatry; 2004 Mar; 37(2):69-73. PubMed ID: 15048614 [Abstract] [Full Text] [Related]